以岭药业：孙公司获得阿那曲唑化学原料药上市申请批准

Core Viewpoint - Yiling Pharmaceutical (002603) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of Anastrozole, a drug used primarily for treating estrogen-related tumors, particularly in postmenopausal women with hormone receptor-positive breast cancer [1]. Company Summary - Yiling Pharmaceutical's subsidiary, Wanyang Hengshui, has successfully obtained a marketing approval for Anastrozole [1]. - Anastrozole is widely used in the treatment of estrogen-related tumors, especially in postmenopausal women with HR+ breast cancer [1].